OncRef

Clinical Trial: NCT02581631

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2023-03-07

Study Overview

Brief Summary

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

Official Title

A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)

Conditions

Non-Hodgkin's Disease

Intervention / Treatment

  • Biological: Nivolumab
  • Drug: Brentuximab Vedotin

Other Study ID Numbers

  • CA209-436
  • 2015-003286-28
  • 2015

Start Date (Actual)

2016-02-11

Primary Completion Date (Actual)

2020-01-16

Study Completion Date (Actual)

2022-02-07

Enrollment (Actual)

145

Study Type

Interventional

Phase

Phase 1, Phase 2